Skip to main content

Mavacamten Dosage

Medically reviewed by Drugs.com. Last updated on Oct 10, 2022.

Applies to the following strengths: 2.5 mg; 5 mg; 10 mg; 15 mg

Usual Adult Dose for Hypertrophic Cardiomyopathy

Starting dose: 5 mg orally once a day
Allowable subsequent doses with titration: 2.5, 5, 10, or 15 mg orally once a day
Maximum dose: 15 mg orally/day

Comments:


Use: For the treatment of patients with symptomatic New York Heart Association (NYHA) class II to III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available

Dose Adjustments

INITIATION PHASE:
5 mg orally once a day


Week 4:

Week 8:

Week 12:

MAINTENANCE PHASE:
Week 12 and every 12 weeks:

TREATMENT INTERRUPTION AT ANY CLINIC VISIT IF LVEF LESS THAN 50%:

Dose increases should be delayed when there is intercurrent illness (e.g., serious infection) or arrhythmia (e.g., atrial fibrillation, other uncontrolled tachyarrhythmia) that may impair systolic function; interruption of this drug should be considered in patients with intercurrent illness.

COADMINISTRATION OF WEAK CYP450 2C19 OR MODERATE CYP450 3A4 INHIBITORS:

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for mavacamten. It includes elements to assure safe use and an implementation system. For additional information: www.accessdata.fda.gov/scripts/cder/rems/index.cfm

US BOXED WARNING:


CONTRAINDICATIONS:

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

General:

Monitoring:

Patient advice:
CAMZYOS REMS Program:
Embryo-Fetal Toxicity:
Instructions for taking this drug:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.